Target Audience and Goal Statement
This activity is intended for cardiologists, primary care providers (PCPs), emergency medicine physicians, nurse practitioners,
nurses, and all clinicians interested in patients living with heart failure (HF).
The goal of this activity is to improve clinicians’ clinical inertia related to the use of lab tests, and, in particular, biomarker-guided therapy in patients with HF.
Upon completion of this activity, participants will:
- Have increased knowledge regarding the
- Latest clinical data and guidelines on the use of natriuretic peptides as a prognostic marker in the setting of HF
- Intensifying treatment of HF to improve outcomes based on biomarker data
- Greater competence related to
- Use of effective team strategies to incorporate biomarker-guided therapy into clinical care for patients with HF
Disclosures
As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of
an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant
financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial
relationships of a spouse or life partner, that could create a conflict of interest.
Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food
and Drug Administration, at first mention and where appropriate in the content.
Moderator

-
James L. Januzzi, MD
Hutter Family Professor of Medicine, Harvard Medical School; Physician, Cardiology Division, Massachusetts General Hospital;
Senior Cardiometabolic Faculty, Baim Institute for Clinical Research, Boston, Massachusetts
Disclosures
Disclosure: James L. Januzzi, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Boehringer Ingelheim Pharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.
Received grants for clinical research from: Abbott Laboratories; Prevencio; Roche; Singulex
Other: Endpoint committees for: AbbVie Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; GE Healthcare; Janssen Pharmaceuticals,
Inc.; Pfizer Inc.; Siemens AG
Dr Januzzi does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA
for use in the United States.
Dr Januzzi does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the
FDA for use in the United States.
Panelists

-
Christopher deFilippi, MD
Vice Chief for Academic Affairs, InovaHeart and Vascular Institute; Director of Chest Pain Unit and Cardiovascular Phase I
Unit, Inova Fairfax Hospital, Falls Church, Virginia; Adjunct Professor of Medicine, Virginia Commonwealth University, Richmond,
Virginia
Disclosures
Disclosure: Christopher deFilippi, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Alere; Fujifilm Corporation; Ortho Clinical Diagnostics; Radiometer Medical ApS; Roche
Diagnostics; Siemens AG
Served as a speaker or a member of a speakers bureau for: Roche Diagnostics
Received grants for clinical research from: Roche Diagnostics
Dr deFilippi does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the
FDA for use in the United States.
Dr deFilippi does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved
by the FDA for use in the United States.

-
Lori B. Daniels, MD, MAS
Professor of Medicine; Director, Coronary Care Unit, University of California, San Diego, La Jolla, California
Disclosures
Disclosure: Lori B. Daniels, MD, MAS, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Roche
Served as a speaker or a member of a speakers bureau for: Janssen Pharmaceuticals, Inc.; Roche
Other: Independent contractor: Siemens Healthcare Diagnostics Inc.
Dr Daniels does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the
FDA for use in the United States.
Dr Daniels does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by
the FDA for use in the United States.

-
Marilyn A. Prasun, PhD, CCNS-BC, CNL, CHFN
Memorial Medical Center, Heart Failure Disease Management Program, Springfield, Illinois; University of Illinois Chicago College
of Nursing
Disclosures
Disclosure: Marilyn A. Prasun, PhD, CCNS-BC, CNL, CHFN, has disclosed no relevant financial relationships.
Ms Prasun does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the
FDA for use in the United States.
Ms Prasun does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by
the FDA for use in the United States.
Editor
CME Reviewer / Nurse Planner
Peer Reviewer
This activity has been peer reviewed and the reviewer has disclosed the following relevant financial relationships:
|Served as advisor or consultant for: Abbott Laboratories; Heartware; Medtronic, Inc.; Thoratec Corporation
Accreditation Statements
In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical
Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC),
to provide continuing education for the healthcare team.
For Physicians
-
Medscape, LLC designates this enduring material for a maximum of 0.50
AMA PRA Category 1 Credit(s)™
. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Medscape, LLC staff have disclosed that they have no relevant financial relationships.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant
to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.
Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity
provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Aggregate participant data will be shared with commercial supporters of this activity.
Contact This Provider
For questions regarding the content of this activity, contact the
accredited provider for this CME/CE activity noted above. For technical
assistance, contact [email protected]
Instructions for Participation and Credit
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability
and acceptance of continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the
activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.
Follow these steps to earn CME/CE credit*:
- Read the target audience, learning objectives, and author disclosures.
- Study the educational content online or printed out.
- Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated
at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it.
Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print
out the tally as well as the certificates from the CME/CE Tracker.
*The credit that you receive is based on your user profile.